Request Hemophilia A Treatment Information

If you are a patient and your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency call 911 immediately. For general medical inquiries, please call CSL Behring Medical Affairs at 1-800-504-5434.

Please contact us for additional information.

All fields marked with an asterisk(*) are required.
*Salutation:  
*Suffix:  
*First Name:  
*Last Name:  
*I am a:
  
This is my:
*Address 1:  
Address 2:
*City :  
*State :
*ZIP Code :  
Telephone Number   
*E-mail Address :  
*Confirm E-mail Address :  


I have questions about the information I am requesting and would like a CSL Behring representative to contact me by:
 

Type in the verification word in the box below and click "Submit."

Verification Word

Submit     Reset

Prior to submitting your information, please review our Privacy Policy

I would like to unsubscribe from this e-mail program.

Next: Important Safety Information »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.